Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy

References

• Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090–3096
   PubMed Web of Science ®Google Scholar
• Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180: S312–S316
   PubMed Web of Science ®Google Scholar
• Feldman BM, Voda A, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 1985;8:261–268
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351–358
   PubMed Web of Science ®Google Scholar
• Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47
   PubMedGoogle Scholar
• Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997;314:228–231
   PubMed Web of Science ®Google Scholar
• Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9–16
   PubMed Web of Science ®Google Scholar
• Constantine GD, Pickar JH. Estrogens in postmenopausal women: recent insights. Curr Opin Pharmacol 2003;3:626–634
   PubMed Web of Science ®Google Scholar
• Gold DT, Silverman SL. Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis? Curr Osteoporos Rep 2007;5:3–7
   PubMedGoogle Scholar
• Pitkin J, Rees MC, Gray S, Lumsden MA, Stevenson J, Williamson J. Managing the menopause – British Menopause Society Council consensus statement on hormone replacement therapy. J Br Menopause Soc 2003;9:129–131
   PubMedGoogle Scholar
• North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003;10:113–132
   PubMed Web of Science ®Google Scholar
• Barnabei VM, Grady D, Stovall DW, et al Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209–1218
   PubMed Web of Science ®Google Scholar
• Jenkins MR, Sikon AL. Update on nonhormonal approaches to menopausal management. Cleve Clin J Med 2008;75:S17–S24
   PubMedGoogle Scholar
• Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084–6091
   PubMed Web of Science ®Google Scholar
• Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 2001;93:1449–1457
   PubMed Web of Science ®Google Scholar
• Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 2008;15:984–992
   PubMed Web of Science ®Google Scholar
• Miller PD, Chines AA, Christiansen C, et al Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525–535
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2008;23:1923–1934
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045–1052
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, et al Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025–1038
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009 Jun 10; [Epub ahead of print]
   Web of Science ®Google Scholar
• Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conguated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018–1024
   PubMed Web of Science ®Google Scholar
• Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039–1044
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens (BZA/CE) for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2009; in press
   Google Scholar
• McGahuey CA, Gelenberg AJ, Laukes CA, et al The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25–40
   PubMed Web of Science ®Google Scholar
• Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas 2005;50:209–221
   PubMed Web of Science ®Google Scholar
• Hilditch JR, Lewis J, Peter A, et al A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161–175
   PubMed Web of Science ®Google Scholar
• Hill CD, Fehnel SE, Bobula JD, Yu H, McLeod LD. Development and preliminary validation of the Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ). Menopause 2007;14:1047–1055
   PubMed Web of Science ®Google Scholar
• Utian W. The true clinical features of post menopause and oöphorectomy, and their response to oestrogen therapy. S Afr Med J 1972;46:732–737
   PubMed Web of Science ®Google Scholar
• Utian WH. Quality of life (QOL) in menopause. Maturitas 2007;57:100–102
   PubMed Web of Science ®Google Scholar
• Ford K, Sowers M, Crutchfield M, Wilson A, Jannausch M. A longitudinal study of the predictors of prevalence and severity of symptoms commonly associated with menopause. Menopause 2005;12:308–317
   PubMed Web of Science ®Google Scholar
• Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661–666
   PubMed Web of Science ®Google Scholar
• Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004. Int J Gynaecol Obstet 2005;88:222–228
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584–602
   PubMed Web of Science ®Google Scholar
• Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005;63:CD004143
   Google Scholar
• Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329–335
   PubMed Web of Science ®Google Scholar